This afternoon, GigCapital2 (GIX.U), the second SPAC effort led by Avi Katz, re-filed their S-1 and amended their terms ahead of their expected IPO pricing next week. Gig2, which is a $130 million TMT focused SPAC, has now added a Right to its Unit and reduced it’s life from 21 months to 18.
Looking more specifically at the changes, Gig2’s new Right is not the standard Right to receive 1/10th of one share, but rather it is 1/20th of one share. However, a right for 1/20th of share on a $130 million deal is rather small. It’s value is only $6.5 million. Will that be enough to satisfy investors?
Well, Gig2 has also reduced the duration on their SPAC by three months, down to 18 months total, to find and close an acquisition. However, they have also added the Crescent Term for this go-around, which adjusts the warrant strike and redemption trigger in the event of the issuance of additional securities in connection with a business combination closing. In light of Constellation Alpha’s recent announcement of their PIPE done at $3.25 per share for their business combination, the Crescent Term feels 100% necessary. It’s not even a sweetener, it just feels mandatory. However, what Gig2 did do to sweeten it is change the threshold at which the Crescent Term kicks in. The $9.20 threshold, which has become customary as of late, has now been given a little extra protective padding with a $9.50 threshold.
All told, Gig2 now has a lot of bells and whistles: one full warrant, a 1/20th right, 18 months, the Crescent Term. And all those bells and whistles mean that investors have been pushing back on this SPAC in light of the fact that the Gig Team still needs to finish Gig1, which is asking for another six months to close their combination with Kaleyra. Investors are not happy that this team is going to have a divided focus. So, in order sell Gig2, this deal needed to be “sweetened-up”. This SPAC will get done, but the real indicator of investor sentiment will be how it trades day-1.
Revised summary of terms below:
Ribbon (NASDAQ:RIBB) has entered into a definitive agreement to combine with Japanese biotech firm DRC Medicine at a pro forma equity value of $422 million. Tokyo-based DRC Medicine manufactures reusable anti-bacterial and anti-allergen wearables and aims to go deeper into the medical device and pharmaceutical space. Transaction Overview Ribbon is expected to provide $50.4 million...
In June 2025, the SPAC market was marked by a notable rise in meeting delays, with adjournments and postponements playing a central role in extension activity, as sponsors navigated a more cautious market environment. Still, several SPACs secured shareholder approvals, and seven business combinations were completed during the month. At the same time, IPO issuance...
An In-Depth Look at SPAC Activity Through the Second Quarter & First Half 2025 Below is a summary of the first half of 2025 SPAC market. If you’d like a pdf copy, you can access the link HERE. Q2 kicked off in chaos. President Trump’s shifting and often contradictory tariff announcements sent markets reeling, driving...
At the SPAC of Dawn The market is set to be showered with new SPACs today as three more SPACs priced their IPOs overnight, bringing 2025’s total to 66, already surpassing the full-year total of 2024. After hours, Ribbon (NASDAQ:RIBB) also added a new SPAC deal to June’s tally just under the wire, bringing the...
NMP Acquisition Corp. (NASDAQ:NMPAU) announced the pricing of its $100 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “NMPAU”, Tuesday, July 1, 2025. The new SPAC plans to combine with a target company that has a resilient business model with potential to scale up revenue. NMP’s management...